See more : CIMB Group Holdings Berhad (1023.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Defence Therapeutics Inc. (DTCFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Defence Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Imerys S.A. (NK.PA) Income Statement Analysis – Financial Results
- Simpson Manufacturing Co., Inc. (SSD) Income Statement Analysis – Financial Results
- Svenska Nyttobostäder AB (publ) (NYTTO.ST) Income Statement Analysis – Financial Results
- Gannett Co., Inc. (GCI) Income Statement Analysis – Financial Results
- HG Semiconductor Limited (6908.HK) Income Statement Analysis – Financial Results
Defence Therapeutics Inc. (DTCFF)
About Defence Therapeutics Inc.
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 13.82K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -13.82K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.86M | 3.58M | 3.76M | 1.16M | 433.45K | 0.00 |
| General & Administrative | 1.25M | 641.39K | 1.04M | 1.36M | 239.73K | 41.95K |
| Selling & Marketing | 1.71M | 1.96M | 2.52M | 341.10K | 0.00 | 41.90K |
| SG&A | 8.79M | 2.90M | 3.56M | 1.70M | 239.73K | 41.95K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.66M | 6.48M | 7.32M | 2.86M | 673.18K | 41.95K |
| Cost & Expenses | 12.66M | 6.48M | 7.32M | 2.86M | 673.18K | 41.95K |
| Interest Income | 0.00 | 6.81K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 262.93K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 70.94K | 13.82K | 7.27M | 2.83M | 673.18K | 41.95K |
| EBITDA | -12.68M | -6.48M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.66M | -6.48M | -7.30M | -2.86M | -673.18K | -41.95K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -537.24K | -387.15K | -70.18K | 0.00 | 0.00 | 40.00K |
| Income Before Tax | -13.19M | -6.87M | -7.34M | -2.86M | -673.18K | -1.95K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 105.00K | 16.59K | -1.16M | -434.13K | -41.95 |
| Net Income | -13.19M | -6.76M | -7.34M | -2.86M | -673.18K | -1.95K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.30 | -0.17 | -0.20 | -0.11 | -0.02 | 0.00 |
| EPS Diluted | -0.30 | -0.17 | -0.20 | -0.11 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 44.63M | 39.66M | 36.08M | 26.60M | 34.80M | 34.80M |
| Weighted Avg Shares Out (Dil) | 44.63M | 39.66M | 36.08M | 26.60M | 34.80M | 34.80M |
Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce a project...
Defence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to give an update...
Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program
Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its...
Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it...
Defence's AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce that Defence's...
Defence's ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its...
Defence's Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio with Ellis Martin
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to share the interview...
Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce its participation...
Defence's AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce the publication...
Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the issuance...
Source: https://incomestatements.info
Category: Stock Reports